Financial Data and Key Metrics Changes - Revenue grew by 5% in Q2 2024, reaching $207.1 million, with organic growth at 3.6% [14] - Adjusted EBITDA increased by 10.2% to $48.8 million, with adjusted EBITDA margins expanding 110 basis points to 23.6% [14] - Adjusted free cash flow was nearly $9 million in the quarter, contributing to a cash flow positive first half of the year [6] Business Line Data and Key Metrics Changes - Medical segment revenue grew by 7.7% with organic growth of 2.6%, driven by Nuclear Medicine [15] - Technology segment revenue increased by 3.7% with organic growth of 4.1%, supported by strong performance in Nuclear Power [17] - Adjusted EBITDA margin for the Medical segment was 34.3%, a 150 basis point expansion from the previous year [15] Market Data and Key Metrics Changes - Order growth was relatively flat compared to the same period last year, with Nuclear Power orders up by more than 15% [5] - Medical segment order growth was approximately 3%, with strong performance in Dosimetry and Nuclear Medicine [7] - Anticipated changes by CMS for the reimbursement of radio diagnostic drugs in the US market are expected to positively impact market dynamics [31] Company Strategy and Development Direction - A strategic partnership agreement was signed with EDF, making Mirion an exclusive content supplier for their nuclear new build projects over the next two decades [3][4] - The company is focusing on margin performance, with a target of 30% long-term EBITDA margin through procurement initiatives and operational improvements [11][36] - Organizational changes include the appointment of a Chief Revenue Officer and the exit from the Medical Lasers and Alignment business to streamline operations [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the overall health of end markets, particularly in Nuclear Power and Nuclear Medicine, despite facing tough order growth comparisons in the second half of the year [5][25] - The company anticipates that the international markets will improve in 2025, driven by strengthening economic conditions [21][29] - Management remains optimistic about the order pipeline and backlog, expecting to maintain or grow backlog levels in the upcoming quarters [24][25] Other Important Information - The company updated its 2024 financial guidance, raising the adjusted EBITDA target to $195 million to $205 million [6][19] - The company completed the redemption of all outstanding public and private warrants, simplifying its capital structure [22] - An Investor Day is planned for early December to share updated strategy and long-term financial targets with the investment community [22] Q&A Session Summary Question: Health of the order pipeline and backlog expectations - Management indicated that while order rates may not be positive year-over-year in the second half, they expect backlog to be up compared to the same period last year [24][25] Question: Impact of the EDF partnership on existing relationships - The partnership streamlines commercial terms and strengthens competitive positioning, providing greater confidence in future investments [27] Question: Anticipated impact of anticorruption dynamics in China - Management expects 2024 to be the low point for the RTQA business, with improvements anticipated in late 2024 and into 2025 [28][29] Question: Potential impact of CMS changes on reimbursement - Management noted that changes in CMS reimbursement protocols could reduce friction for the prescription of radio diagnostic procedures, potentially increasing demand for their products [31][43] Question: Capital structure improvements - Management stated that significant progress has been made on the balance sheet, with a focus on executing growth plans and improving margins [32][33] Question: Visibility on cash flow generation - Management expressed confidence in generating cash in the second half of the year, aligning with historical performance [40]

SHANGHAI, May 24, 2024 /PRNewswire/ -- The9 Limited (Nasdaq: NCTY) (the "Company"), an established Internet company, today announced that its wholly-owned subsidiary China Crown Technology Limited ("China Crown"), a company incorporated in Hong Kong, entered into an exclusive publishing license agreement (the "License Agreement") with Wemade Co., Ltd. ("Wemade"). Pursuant to the License Agreement, China Crown will exclusively publish and service the new MIR M game in mainland China, in both Mobile and PC ve ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-39352 Mirion Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 83-0974996 (State or ...

Exhibit 99.1 Mirion Announces First Quarter 2024 Financial Results and Reaffirms Full Year Guidance News Release Other modeling and guidance assumptions include the following: • Revenues for the first quarter increased 5.8% to $192.6 million, compared to $182.1 million in the same period in 2023. • Net loss was $26.5 million in the first quarter, compared to a net loss of $42.9 million in the same period last year. Adjusted EBITDA was $39.5 million, a 7.9% increase from $36.6 million in the same period last ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-39352 Mirion Technologies, Inc. (Exact name of registrant as specified in its charter) (I.R.S. Employer ...

Financial Data and Key Metrics Changes - The company reported a record total revenue of $801 million for the year, with organic revenue growth of 5% in Q4 and 9.3% for the full year [9][26] - Adjusted EBITDA for Q4 was $61 million, contributing to a full year adjusted EBITDA of $181 million, marking a record performance [9][10] - Adjusted free cash flow in Q4 was $62 million, with net leverage finishing the year at 3.0 times EBITDA, beating expectations [10][33] Business Line Data and Key Metrics Changes - The Medical segment achieved organic growth of just under 10% in Q4, with total revenue growth of 6.8% [9][27] - Technologies segment revenue grew by 5.1% in Q4, with organic growth of 3% [37] - Medical adjusted EBITDA margins expanded by over 500 basis points to 38.5% in Q4, while Technologies adjusted EBITDA margins contracted by 70 basis points to 29.5% [28][30] Market Data and Key Metrics Changes - The company experienced a 30% organic order growth in Q4, leading to a record backlog and a 15% increase compared to year-end 2022 [8] - The Nuclear Medicine market is expected to be a strong growth engine, supported by the ec2 acquisition [15][16] - The company noted robust order activities in the nuclear power sector, with political support for nuclear energy improving globally [18][19] Company Strategy and Development Direction - The company plans to release over 40 new product introductions in 2024, significantly increasing from 10 in 2023 [20] - Focus areas for 2024 include margin expansion, enhanced free cash flow conversion, and opportunistic M&A [22][23] - The company aims for a five-year goal of achieving 30% adjusted EBITDA margins [22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustained momentum and growth, supported by a healthy backlog and market conditions [8][47] - The company anticipates organic revenue growth of 4% to 6% for 2024, with adjusted EBITDA guidance of $193 million to $203 million [11][34] - Management highlighted the importance of operational execution and cash flow conversion as key focuses for 2024 [45][99] Other Important Information - The Medical segment now constitutes 38% of total company revenue and 44% of total company EBITDA [16] - The company is committed to capital efficiency and selective M&A, with a robust pipeline for potential acquisitions [23][41] Q&A Session Summary Question: Thoughts on new product introductions and revenue growth - Management emphasized their commitment to innovation and the expectation that new products will drive predictable, recurring revenue growth [56] Question: Margin expansion opportunities in Technologies - Management acknowledged challenges in the French market but expressed confidence in corrective actions and improvements for 2024 [60][61] Question: Insights on order growth and revenue translation - Management noted that order growth is longer cycle in nature, providing visibility for future revenue [63] Question: Expectations for pricing and cost in 2024 - Management indicated a focus on ensuring price-cost is rate-positive while doubling down on cost management initiatives [84] Question: Headwinds in the healthcare industry and their impact - Management discussed the impact of Medicare reimbursement changes but remained optimistic about growth driven by global demand and aging demographics [89] Question: Radiopharmaceutical market trends and expectations - Management expressed bullishness on the radiopharmaceutical market, particularly in theranostic applications, and highlighted the importance of recent acquisitions [91] Question: 2024 guidance context and growth expectations - Management provided context for the 5% to 7% growth guidance, citing strong order growth and historical performance as supportive factors [94]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-39352 Mirion Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 83-0974996 (Stat ...

Mirion Technologies, Inc. (NYSE:MIR) Q3 2023 Results Conference Call November 2, 2023 12:00 PM ET Company Participants Alex Gaddy - SVP, Strategy Larry Kingsley - Chairman Tom Logan - CEO Brian Schopfer - CFO Conference Call Participants Joe Ritchie - Goldman Sachs Andy Kaplowitz - Citi Group Chris Moore - CJS Securities Operator Greetings, and welcome to the Mirion Third Quarter 2023 Earnings Conference Call. [Operator Instructions]. As a reminder, this conference is being recorded. It is now my pleasure ...

PART I - FINANCIAL INFORMATION [Financial Statements (Unaudited)](index=5&type=section&id=ITEM%201.%20Financial%20Statements%20(Unaudited)) Mirion's total revenues increased by 11.9% to $379.3 million, with net loss narrowing to $71.3 million, primarily due to the absence of a goodwill impairment charge [Condensed Consolidated Balance Sheets](index=6&type=section&id=Unaudited%20Condensed%20Consolidated%20Balance%20Sheets) Total assets slightly decreased to $2.70 billion, while total liabilities decreased to $1.13 billion, and stockholders' equity increased to $1.56 billion Condensed Consolidated Balance Sheet Highlights | Account | June 30, 2023 (in millions) | December 31, 2022 (in millions) | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $87.4 | $73.5 | | Goodwill | $1,425.2 | $1,418.0 | | Intangible assets, net | $586.7 | $650.4 | | Total assets | $2,696.3 | $2,738.7 | | **Liabilities & Equity** | | | | Notes payable to third-parties, non-current | $677.8 | $801.5 | | Warrant liabilities | $49.6 | $30.5 | | Total liabilities | $1,131.8 | $1,271.5 | | Total stockholders' equity | $1,564.5 | $1,467.2 | [Condensed Consolidated Statements of Operations](index=7&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Operations) Q2 2023 revenues increased 12.2% to $197.2 million, with net loss significantly improving to $28.4 million due to the absence of goodwill impairment Key Operating Results | Metric | Q2 2023 (in millions) | Q2 2022 (in millions) | YTD 2023 (in millions) | YTD 2022 (in millions) | | :--- | :--- | :--- | :--- | :--- | | Total revenues | $197.2 | $175.8 | $379.3 | $339.0 | | Gross profit | $88.0 | $79.0 | $167.1 | $143.4 | | Loss from operations | $(10.6) | $(74.6) | $(24.2) | $(108.2) | | Goodwill impairment | $0.0 | $55.2 | $0.0 | $55.2 | | Net loss | $(28.4) | $(59.3) | $(71.3) | $(78.3) | | Net loss per share | $(0.14) | $(0.32) | $(0.36) | $(0.42) | [Condensed Consolidated Statements of Cash Flows](index=11&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash from operations decreased to $4.4 million, while financing activities provided $21.8 million, largely from a $150 million stock issuance used for debt repayment Cash Flow Summary | Activity | Six Months Ended June 30, 2023 (in millions) | Six Months Ended June 30, 2022 (in millions) | | :--- | :--- | :--- | | Net cash provided by operating activities | $4.4 | $28.0 | | Net cash used in investing activities | $(12.9) | $(14.5) | | Net cash provided by (used in) financing activities | $21.8 | $(2.4) | | **Net increase in cash** | **$14.1** | **$6.7** | [Note 3: Disposal of Business](index=16&type=section&id=Note%203.%20Disposal%20of%20Business) The company sold its Biodex Rehabilitation business, recording a $6.2 million loss on sale due to uncollectible deferred payments - The company sold its Rehab business for **$1.0 million** in cash and **$7.0 million** in deferred payments[66](index=66&type=chunk) - A loss of **$6.2 million** was recorded on the sale in Q2 2023, as the collection of the **$7.0 million** deferred payment was deemed not probable due to the buyer's financial instability[66](index=66&type=chunk) [Note 8: Goodwill and Intangible Assets](index=18&type=section&id=Note%208.%20Goodwill%20and%20Intangible%20Assets) No goodwill impairment was recognized in 2023, contrasting with a $55.2 million impairment in 2022 due to the Russia-Ukraine conflict - No goodwill impairment was recognized for the six months ended June 30, 2023[81](index=81&type=chunk) - In the prior year period (six months ended June 30, 2022), a **$55.2 million** non-cash goodwill impairment loss was recognized in the Technologies segment's RMS reporting unit[80](index=80&type=chunk) - The 2022 impairment was triggered by the Russia-Ukraine conflict and the resulting termination of a contract for a nuclear power plant in Finland, which had a remaining performance obligation of approximately **$67 million**[79](index=79&type=chunk) [Note 16: Segment Information](index=30&type=section&id=Note%2016.%20Segment%20Information) Technologies segment revenue grew 18.5% to $129.2 million, swinging to a $12.8 million operating income, while Medical segment revenue grew 1.8% to $68.0 million Segment Revenues | Segment | Q2 2023 (in millions) | Q2 2022 (in millions) | YTD 2023 (in millions) | YTD 2022 (in millions) | | :--- | :--- | :--- | :--- | :--- | | Medical | $68.0 | $66.8 | $134.4 | $126.9 | | Technologies | $129.2 | $109.0 | $244.9 | $212.1 | | **Total** | **$197.2** | **$175.8** | **$379.3** | **$339.0** | Segment (Loss) Income from Operations | Segment | Q2 2023 (in millions) | Q2 2022 (in millions) | YTD 2023 (in millions) | YTD 2022 (in millions) | | :--- | :--- | :--- | :--- | :--- | | Medical | $(3.1) | $(2.2) | $(2.4) | $(8.9) | | Technologies | $12.8 | $(46.5) | $18.3 | $(49.0) | | **Total Segment** | **$9.7** | **$(48.7)** | **$15.9** | **$(57.9)** | [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=39&type=section&id=ITEM%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Q2 2023 revenues increased 12.2% to $197.2 million, with net loss improving to $28.4 million, and Adjusted EBITDA reaching $44.3 million [Results of Operations](index=46&type=section&id=Results%20of%20Operations) Q2 2023 revenues grew 12.2% to $197.2 million, with operating loss significantly narrowing due to the absence of goodwill impairment and lower SG&A expenses - **Q2 2023 vs Q2 2022:** - **Revenues:** Increased by **$21.4 million** (12.2%) to **$197.2 million**[210](index=210&type=chunk) - **Operating Loss:** Improved to **$(10.6) million** from **$(74.6) million**, mainly due to the absence of a **$55.2 million** goodwill impairment in 2023[213](index=213&type=chunk) - **SG&A:** Decreased by **$7.0 million** to **$84.0 million**, driven by lower stock-based compensation and professional fees[220](index=220&type=chunk) - **YTD 2023 vs YTD 2022:** - **Revenues:** Increased by **$40.3 million** (11.9%) to **$379.3 million**[240](index=240&type=chunk) - **Operating Loss:** Improved to **$(24.2) million** from **$(108.2) million**[244](index=244&type=chunk) - **SG&A:** Decreased by **$12.8 million** to **$169.1 million**[250](index=250&type=chunk) [Non-GAAP Financial Measures](index=41&type=section&id=Non-GAAP%20Financial%20Measures) Adjusted EBITDA for Q2 2023 increased to $44.3 million, with YTD 2023 Adjusted EBITDA reaching $80.9 million, reflecting various non-GAAP adjustments Reconciliation of Net Loss to Adjusted EBITDA | Metric | Q2 2023 (in millions) | Q2 2022 (in millions) | YTD 2023 (in millions) | YTD 2022 (in millions) | | :--- | :--- | :--- | :--- | :--- | | Net loss | $(28.4) | $(59.3) | $(71.3) | $(78.3) | | Adjustments (Interest, Tax, D&A, etc.) | $55.6 | $23.4 | $95.8 | $81.4 | | EBITDA | $24.8 | $(13.5) | $37.1 | $16.3 | | Further Adjustments (Stock Comp, Warrants, etc.) | $19.5 | $56.1 | $43.8 | $61.2 | | **Adjusted EBITDA** | **$44.3** | **$42.6** | **$80.9** | **$77.5** | [Liquidity and Capital Resources](index=56&type=section&id=Liquidity%20and%20Capital%20Resources) Cash and cash equivalents were $87.4 million, with operating cash flow at $4.4 million, and financing activities providing $21.8 million from a $150 million equity issuance - Cash and cash equivalents stood at **$87.4 million** as of June 30, 2023[282](index=282&type=chunk) - Net cash provided by operating activities decreased to **$4.4 million** for YTD 2023 from **$28.0 million** for YTD 2022[289](index=289&type=chunk) - In Q1 2023, the company raised **$150.0 million** from a direct stock offering and used approximately **$127 million** to repay outstanding debt, resulting in a **$2.6 million** loss on debt extinguishment[204](index=204&type=chunk)[291](index=291&type=chunk) [Quantitative and Qualitative Disclosures about Market Risk](index=58&type=section&id=ITEM%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) No material changes were reported regarding the company's market risk disclosures, including interest rate, foreign currency, and commodity price risks - There were no material changes to the company's disclosures regarding market risk during the quarter[295](index=295&type=chunk) [Controls and Procedures](index=59&type=section&id=ITEM%204.%20Controls%20and%20Procedures) Disclosure controls and procedures were deemed ineffective due to a material weakness in general IT controls at the French division, with remediation efforts ongoing - The CEO and CFO concluded that disclosure controls and procedures were not effective as of June 30, 2023[297](index=297&type=chunk) - A material weakness persists related to general IT controls (GITCs) at the company's division in France, specifically concerning program change-management and user access[299](index=299&type=chunk) - Remediation plans are in progress, including educating IT control owners, enhancing controls, and adding manual business process controls to mitigate risks[302](index=302&type=chunk) PART II - OTHER INFORMATION [Legal Proceedings](index=60&type=section&id=ITEM%201.%20Legal%20Proceedings) The company faces legal proceedings, including a $19.3 million claim for liquidated damages and a $10.5 million demand from a Russian customer, which management deems without merit - In April 2023, a Russian customer made a claim for **$19.3 million** in liquidated damages for project delays[114](index=114&type=chunk) - In June 2023, the same customer demanded the return of **$10.5 million** in payments related to a cancelled nuclear power plant project in Finland[114](index=114&type=chunk) - Management views both the claim and the demand as without merit and intends to defend against them vigorously[114](index=114&type=chunk) [Risk Factors](index=60&type=section&id=ITEM%201A.%20Risk%20Factors) The Russia-Ukraine conflict continues to pose significant risks, including a $10.5 million demand and a $19.3 million claim from a Russian entity, with uncertain resolution under Russian law - The Russia-Ukraine conflict continues to pose a significant risk, causing project delays, cancellations, and supply chain disruptions[308](index=308&type=chunk) - A Russian state-owned entity has demanded the return of approximately **$10.5 million** for a cancelled Finnish project and claimed **$19.3 million** in penalties for delays on an active Hungarian project[308](index=308&type=chunk) - The company views the claims as without merit but acknowledges uncertainty in their resolution, as the contract is governed by Russian law[308](index=308&type=chunk)

Financial Data and Key Metrics Changes - The company reported organic revenue growth of nearly 8.5% compared to the same period last year, with total revenue growing by 12.2% in the second quarter [46][48] - Adjusted EBITDA was up 4%, with quarterly revenue reaching $197.2 million and adjusted EBITDA margins contracting 170 basis points to 22.5% [50][46] - Free cash flow was $2.3 million in the second quarter, consistent with expectations, but challenged by higher interest expenses and net working capital dynamics [46][67] Business Line Data and Key Metrics Changes - The Medical segment saw revenue up 1.8% with organic growth of 6.9%, driven by strength in radiation therapy quality assurance [51][48] - The Technologies segment experienced revenue growth of 18.5% with organic growth of 9.3%, supported by strong performance in labs and research as well as nuclear power [52][48] - Order growth in the first half was 6%, with notable contributions from labs and research, defense, and diversified industrials [47] Market Data and Key Metrics Changes - The company noted strong demand in the nuclear markets, with a healthy installed base and increasing engagement [14][61] - The defense sector showed significant growth, with first half order growth of 28%, reflecting increased demand due to geopolitical factors [28][61] - The company anticipates easing unfavorable geographic and product mix impacts in the third and fourth quarters [44] Company Strategy and Development Direction - The company is focused on improving operational excellence, particularly in free cash flow and margins, with a goal to enhance inventory turns [62][49] - There is a commitment to reducing leverage to 3.1x or lower by the end of the year while remaining active in M&A opportunities [19][40] - The integration of the SIS acquisition is progressing well, with expectations for it to be margin neutral within the planning horizon [63][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the market dynamics and order intake, indicating a favorable demand environment for the second half of the year [39][61] - The company is optimistic about the nuclear market's potential and expects continued strength in new build activities [6][28] - There is a focus on mitigating supply chain risks and improving working capital efficiency to enhance cash flow generation [22][67] Other Important Information - The company has updated its financial guidance for 2023, expecting revenue growth of 8% to 10% and adjusted free cash flow guidance of $45 million to $75 million [53][60] - The divestiture of the Biodex physical rehab business impacted reported revenue by over 5% in the quarter [66] Q&A Session Summary Question: Update on M&A pipeline and potential - The M&A pipeline remains vigorous, with a commitment to reducing leverage while exploring smaller potential deals [19] Question: Insights on Technologies segment strength - The Technologies segment is experiencing strong order intake and backlog coverage, with a positive outlook for year-over-year dynamics [11][12] Question: Pricing dynamics and potential wildcards - The company expects improvements in pricing as the year progresses, with a 4% price contribution noted in the quarter [65][36] Question: Integration of SIS and margin impact - The integration of SIS is going well, with expectations for it to contribute positively to margins in the future [30][33] Question: Visibility on dosimetry orders and Instadose technology - While not providing specific guidance for 2024, the company anticipates that the commercialization of the third generation of Instadose technology will positively impact growth [37] Question: Progress in new nuclear plant construction - Management noted that engagement in new build activities is picking up, indicating progress compared to the previous year [38]